T1	Phenotype	24 41	symptom endpoints
T2	Pharmacodynamic_phenotype	63 83	efficacy outcomes in
T3	Chemical	102 114	gefitinib in
T4	Disease	129 162	EGFR mutation-positive tumors and
T5	Chemical	163 190	carboplatin / paclitaxel in
T6	Disease	210 236	mutation-negative tumors .
R1	isAssociatedWith	Arg1:T1	Arg2:T2
R2	isAssociatedWith	Arg1:T1	Arg2:T3
R3	isAssociatedWith	Arg1:T1	Arg2:T4
R4	isAssociatedWith	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T1	Arg2:T6
R6	isAssociatedWith	Arg1:T2	Arg2:T1
R7	treats	Arg1:T3	Arg2:T1
R8	treats	Arg1:T3	Arg2:T4
R9	treats	Arg1:T3	Arg2:T5
R10	treats	Arg1:T3	Arg2:T6
R11	treats	Arg1:T4	Arg2:T6
R12	treats	Arg1:T5	Arg2:T1
R13	influences	Arg1:T5	Arg2:T3
R14	treats	Arg1:T5	Arg2:T4
R15	treats	Arg1:T5	Arg2:T6
R16	isAssociatedWith	Arg1:T6	Arg2:T1
R17	isAssociatedWith	Arg1:T6	Arg2:T2
R18	influences	Arg1:T6	Arg2:T3
R19	treats	Arg1:T6	Arg2:T4
R20	influences	Arg1:T6	Arg2:T5
